Department of Digital Transformation and Ogden’s Catalyst Accelerator Announce Challenge Statement and Open Applications for Fall 2024 Cohort
June 03, 2024 16:29 ET
|
Catalyst Accelerator
Ogden, UT, June 03, 2024 (GLOBE NEWSWIRE) -- The Ogden Catalyst Accelerator is pleased to announce the opening of applications for its Fall 2024 cohort, focused on addressing the critical challenge...
Genesis Offers New Tools and Incentives to Financial Industry Software Developers
June 03, 2024 08:00 ET
|
Genesis Global
Genesis Global announced new technologies and changes in its engagement model to drive broad industry adoption of its application platform.
USI Insurance Services Launches PATH, a Proprietary Technology-Enabled Risk Control Platform
June 03, 2024 08:00 ET
|
USI Insurance Services
VALHALLA, N.Y., June 03, 2024 (GLOBE NEWSWIRE) -- USI Insurance Services (“USI”), a world leader in risk management, employee benefit and retirement plan consulting, today announced the launch of...
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
May 31, 2024 12:00 ET
|
Alberta Cancer Foundation
Alberta Cancer Foundation announces new Breakthrough Fund recipient, driving commercial success of cancer research breakthroughs
Local startup Oncobiotix
Mountain America Credit Union’s Christine Ebert Recognized Among Utah Business 30 Women to Watch
May 31, 2024 10:00 ET
|
Mountain America Credit Union
SANDY, Utah, May 31, 2024 (GLOBE NEWSWIRE) -- Christine Ebert, vice president of project management at Mountain America Credit Union, was recently recognized by Utah Business as one of the 30 Women...
Novartis Phase III data confirm sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria
May 30, 2024 18:01 ET
|
Novartis Pharma AG
Patients treated with remibrutinib experienced improvements in weekly urticaria activity scores (UAS7) observed as early as Week 1 and sustained to 1 year (Week 52)1Remibrutinib, an oral Bruton’s...
Incorta launches the first Operational GenAI with leading RAG and LLM providers
May 28, 2024 09:12 ET
|
Incorta, Inc.
FOSTER CITY, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Incorta, a leading operational lakehouse, today announces the launch of Operational GenAI, an unlimited and enterprise GenAI solution built on...
Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction further advancing company's IgA nephropathy (IgAN) portfolio
May 25, 2024 06:15 ET
|
Novartis Pharma AG
In the ALIGN study, atrasentan, in addition to supportive care with a renin-angiotensin system (RAS) inhibitor, demonstrated a statistically significant 36.1% proteinuria (protein in urine) reduction...
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
May 25, 2024 06:00 ET
|
Novartis Pharma AG
Secondary endpoint data for estimated glomerular filtration rate (eGFR) showed numerical improvement over 6 months vs. placebo1; additional 6-month open-label data to be presented at a future medical...